We observed that the inhibition of PKCδ was sufficient to decrease CML CD34+ cell clonogenicity by 75%, with a very homogeneous response among patients compared to that realized with IMA, which reduced clonogenicity by only 60% and showed more heterogeneous responses (Figure 5B). The gene discussed is PRKCD; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.